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pharmaceutically active anions†
Joa˜o M. M. Arau´jo,‡*a Catarina Florindo,‡a Ana B. Pereiro,a Nicole S. M. Vieira,a
Ana A. Matias,ac Catarina M. M. Duarte,ac Lu´ıs P. N. Rebeloa and Isabel M. Marrucho*abNovel ionic liquids (ILs) containing cholinium as a benign cation
combined with anions based on ﬁve active pharmaceutical ingredients
(APIs), namely, nalidixic acid, niﬂumic acid, 4-amino-salicylic acid,
pyrazinoic acid and picolinic acid, were prepared via a simple and
sustainable two-step anion exchange reaction. The solubility of the
prepared pharmaceutically active ILs (API-ILs) in both water and
simulated biological ﬂuids at 25 C and 37 C, aswell as the solubility of
the parent APIs, were measured. Further, in vitro cytotoxicity levels for
both cholinium-based API-ILs and parent APIs were established using
two diﬀerent human cells lines, namely Caco-2 colon carcinoma cells
and HepG2 hepatocellular carcinoma cells. Herein, the dual nature of
ILs is exploited by combining the cheap, available and essential
nutrient cholinium cation with pharmaceutically active anions,
upgrading the chemical, physical and biopharmaceutical properties,
particularly melting point, aqueous solubility and the potential to
penetrate cell membranes of the parent APIs, without impair their
cytotoxicity response which prompt opportunities for creating further
advances in pharmaceutical challenges.Introduction
According to the commonly accepted denition, ILs are salts
with a melting point below the conventional temperature of
100 C.1 Due to their unique chemical and physical properties, Universidade Nova de Lisboa, Apartado
mda@itqb.unl.pt; Web: http://www.itqb.
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olo´gica, Apartado 12, 2781 901 Oeiras,
ESI) available: Experimental procedure,
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PIs in the buﬀer solutions at 37 C (PAS,
d cytotoxicity assay details. See DOI:
2addressable by their dual-functional nature and their design
exibility which allow target synthesis of “tuned”materials, ILs
display considerable potential in a variety of biomedical topics,
including the formulation of biologically active compounds for
delivery into the human body,2 7 as well as the solubilisation of
biochemical compounds of paramount importance such as
DNA8,9 and nucleic acid bases.10 12
An emerging research eld of interest is the use of ILs in
pharmaceutical applications. The potential of ILs as pharma-
ceutical solvents to dissolve poorly soluble APIs has been
reported.13 Additionally, their use as drug delivery vehicles has
been investigated.14 16 Moreover, some works have taken a
further step in developing ILs that are themselves the APIs.2 7
The rst attempt to specically prepare API-ILs was accom-
plished by Rogers and co-workers,2 who reported on the potential
of this poorly exploited drug phase. Several studies have been
recently published on API-ILs by an increasing number of research
groups. Our group reported novel ILs containing antibiotics,
ampicillin as an API anion5,7 and tetracycline as an API cation,6
while Bica et al.17 reported ILs based on analgesic, anti-pyretic
and anti-inammatory compounds (acetylsalicylic and salicylic
acids). Hough et al.2 and MacFarlane and co-workers3 addressed
API-ILs containing various active cations and anions. Hough-
Troutman et al.18 exploited the dual nature of ILs by combining
anti-bacterial quaternary ammonium cations with articial
sweetener anions. Also, Cybulski and co-workers19 prepared ILs
based on antiseptic/disinfectant cations and amino acids anions,
which were found to be very eﬀective against bacteria and fungi.
The pharmaceutical industry has attributed more than 40%
of the failures in new drug development to poor bio-
pharmaceutical properties, particularly poor water solubility.20
Water insolubility can shelve or invalidate new drug develop-
ment, and thus signicantly aﬀect the much needed reformu-
lation of currently marketed products.21 23 In recent years,
approximately 70% of new drug candidates have shown poor
aqueous solubility.24 Nowadays, close to 40% of the marketed
immediate-release oral drugs are categorized as practically
insoluble (<0.1 mg ml1).25 The poor aqueous solubility of drugThis journal is © The Royal Society of Chemistry 2014
Fig. 1 Two-step anion exchange reaction and chemical structure of
the ions used for preparation of the cholinium-based API-ILs. The
abbreviations of the prepared cholinium-based API-ILs are as follow,
(1) [N1112OH][NAL], (2) [N1112OH][PYR], (3) [N1112OH][PIC], (4) [N1112OH][NIF]
and (5) [N1112OH][PAS].
Communication RSC Advancescandidates plays one of the major roles in drug research and
development. The low aqueous solubility of orally administered
drugs leads to limited dissolution rate and low bioavailability.
Compounds with aqueous solubility lower than 0.1 mg ml1
mostly present dissolution-limited absorption.26 In such cases,
dose escalation is required until the blood concentration attains
the therapeutic drug concentration range. However, this
procedure might originate topical toxicity in the gastrointes-
tinal tract upon oral administration, and impels to a reduction
in patient compliance. Additionally, the manufacturing costs
increase since a large amount of API is needed in the drug
development and production.
Following the high intrinsic value of APIs and the relevance
of structure and composition in the context of both intellectual
property and bioavailability, a systematic approach to the
development of a new broad class of APIs has been put forward
in recent years, API-ILs.2 API-ILs are attractive to the pharma-
ceutically industry because they oﬀer multiple opportunities to
modify the chemical and physical properties of an API (e.g.
melting point, chemical stability, physical stability, solubility,
bioavailability, dissolution rate) with a relatively simple
approach.5 Additionally, it allows a synergetic action upon the
appropriate selection of the counter-ion. API-ILs counter-ions
that are suitable for pharmaceutical use remain to be fully
enumerated, but over 370 substances are listed as “Generally
Regarded As Safe (GRAS)” by the FDA (U.S. Food and Drug
Administration), including vitamins, food additives and other
well-accepted substances. Additionally, exceedingly safe drugs,
such as paracetamol and aspirin, are also valid counter-ions.
The access of ILs into the biosciences has been delayed
mainly due to the toxicity of the counter-ions.5 An alternative
approach capable of overcoming this drawback is the develop-
ment of ILs from components with well characterized biode-
gradable and toxicological properties. Natural metabolites are
superior candidates to design low toxicity ILs. A striking
example is the cholinium cation (cf. Fig. 1), formerly classied
as vitamin B4.27 The combination of this cation as well as
related ones (e.g. betainium cations) with appropriate anions is
a suitable approach to form “drinkable” ILs.5,28,29 Albeit, the
inclusion of a systematic evaluation of the toxicological prop-
erties is considered mandatory for IL product development.30
In the present study, the development of novel API-ILs
through the combination of the chemical and biological prop-
erties of the cholinium cation with those of pharmaceutically
active anions, exploiting the dual nature of ILs, has been
accomplished. Cholinium is an essential nutrient,31 which is
necessary for the normal growth of cells and its dietary de-
ciency in adults animals and humans causes fatty liver as well as
other abnormalities. Additionally, ILs with the benign choli-
nium cation were found to be highly biocompatible,32 e.g. the
cholinium alkanoates are less toxic than their corresponding
sodium salts. Also, the cytotoxicity of a family of cholinium
phosphate ILs has been measured for J774 murine macrophage
cell line, revealing that the toxicity essentially depends on the
employed anion.33 The structures of the APIs brought into play
in this work are depicted in Fig. 1, and their most relevant
attributes are briey described in the ESI.†This journal is © The Royal Society of Chemistry 2014Herein, we report a straightforward synthetic procedure,
characterization and thermal properties of ve novel ILs based
on the cholinium cation combined with anions based on the
following APIs – nalidixic acid (NAL), niumic acid (NIF), 4-
amino-salicylic acid (PAS), pyrazinoic acid (PYR) and picolinic
acid (PIC). Further, the solubility in water at 25 C and buﬀer
solutions suitable for dissolution testing at 37 C (body
temperature) were evaluated. In the latter case, simulated
gastric uid without enzymes – interchangeable with 0.1 N HCl
(pH 1.0), simulated intestinal uid without enzymes – inter-
changeable with phosphate standard buﬀer pH 6.8, and a 0.15
M NaCl – isotonic ionic strength solution were used. The solu-
bility of the parent APIs were also estimated. Additionally, to
ascertain whether our a priori assumption of a high biocom-
patibility of the cholinium-based API-ILs is valid, we have per-
formed in vitro cytotoxicity assays with two diﬀerent human
cells lines, namely Caco-2 colon carcinoma cells and HepG2
hepatocellular carcinoma cells. We report experimental data on
the cytotoxicity of the cholinium-based API-ILs and parents APIs
in order to identify the toxicity levels for continued development
in pharmaceutical formulations.
Results and discussion
Cholinium serves many physiological functions due to its
incorporation in membrane components, signaling mole-
cules, and neurotransmitters.34 Because of the prevalence of
cholinium in the human body, cholinium-based API-ILs have
been prepared and investigated within the frame of this workRSC Adv , 2014, 4, 28126 28132 | 28127
Table 1 Thermal properties (Tg, Tm and Tonset) of the cholinium-based
API-ILs. The melting points of the parent APIs are also depicted to
highlight the successful reduction of the initial melting points
Compound Tg
a/C Tm
b/C Tonset
c/C
[N1112OH][NIF] 19.45 4.70 (lit.,
41 205.24) 188.47
[N1112OH][PIC] 52.45 (lit.,
42 137 138) 176.28
[N1112OH][NAL] 16.81 76.07 (lit.,
43 227 229) 179.41
[N1112OH][PYR] 47.15 81.31 (lit.,
44 225) 179.41
[N1112OH][PAS] 19.93 117.40 (lit.,
45 151 153) 171.04
a Glass transition temperatures (Tg) and.
b Melting temperatures (Tm)
were determined by DSC at a heating rate of 1 C min 1 ([N1112OH]
[NIF]), 5 C min 1 ([N1112OH][PIC]), 1 C min
1 ([N1112OH][NAL]), 5 C
min 1 ([N1112OH][PYR]), 1 C min
1 ([N1112OH][PAS]), aer cooling to
90 C under nitrogen. The melting temperatures of the parent APIs
are also depicted enclosed in parentheses. c Decomposition
temperatures (T onset) were measured by TGA with a heating rate of 1C min 1 under nitrogen.
Fig. 2 DSC curves of [N1112OH][PYR] at two diﬀerent scan rates, 10 C
min 1 and 5 C min 1. This cholinium-based API-IL shows thermal
hysteresis. [N1112OH][PYR] remains liquid upon cooling (subcooled
liquid state) until it reaches a glass transition at low temperature in the
heating part of the cycle. Upon heating above the glass transition,
[N1112OH][PYR] exhibits an exothermic crystallization peak (cold crys-
tallization temperature) followed by an endothermic melting peak.
RSC Advances Communicationfor their potential use in pharmaceutical applications.
Plus, cholinium salts such as the chloride ([N1112OH]Cl – the
cation “supplier”, cf. Fig. 1) are nowadays cost-eﬃcient
chemicals, produced on a scale of millions per year.
Therefore, cholinium-based API-ILs should not only be
biocompatible, but also oﬀer economic advantages. The
structures of the cholinium-based API-ILs prepared in this
study are shown in Fig. 1.
ILs are conventionally prepared by anion exchange of halide
salts with metal salts or acids.35 One of the major concerns
within the IL community, is the need to prepare halide-free ILs.
These inorganic contaminations are a drawback for the alkaline
salt metathesis synthetic route, that can be avoided by the use of
acids instead of salts.36 However, due to the fact that an anion
exchange by weaker acids than hydrohalic acids cannot be
eﬃciently performed,28 this method is unsuitable for the
present study. Instead, we implemented ion exchange resin
methods, as develop by Ohno et al., which are being successfully
used as alternative anion exchange processes.37 Therefore, the
cholinium-based API-ILs were synthesised via the two-step
anion exchange reaction illustrated in Fig. 1. In this synthetic
procedure, an anion exchange resin in the OH form (SUPELCO
AMBERLITE IRN78) was used to prepare an aqueous solution of
cholinium hydroxide ([N1112OH][OH]) from cholinium chloride
([N1112OH]Cl) aqueous solution. The [N1112OH][OH] was then
neutralized by the dropwise addition of adequate aqueous API
solution. Neat cholinium-based API-ILs were obtained aer
eliminating the excess water and API by evaporation and
washing, respectively. All isolated products were completely
characterized by 1H and 13C NMR, ESI mass spectra and
elemental analysis in order to check their expected structures
and nal purities. Additionally, the quantitative integration of
their characteristic 1H NMR resonance peaks unfold the
expected cation/anion correlations. The water content, deter-
mined by Karl Fischer titration, was less than 0.05 wt%. The
chloride content (halide impurities), quantied by a Chloride
Ion Selective Electrode, was found to be less than 0.04 wt%. The
prepared cholinium-based API-ILs were further characterized by
thermogravimetric analysis (TGA) and diﬀerential scanning
calorimetry (DSC).
Despite the fact that several studies38 40 assumed that the
inclusion of carboxylic acid groups in ILs would readily produce
strong hydrogen bonds, and consequently high melting points
(Tm) or glass transition temperatures (Tg), some works prepared
low-melting ILs incorporating carboxylate groups.28,32 In this
work, four out of the ve prepared cholinium-based API-ILs
have Tm and Tg below 100 C, and two of them ([N1112OH][NIF]
and [N1112OH][PIC]) are liquid at room temperature.
[N1112OH][PIC] shows nomelting or freezing behavior in the DSC
measurements, even when slowly heated and cooled at a scan
rate of 1 C min1. Only [N1112OH][PAS] was obtained as a
molten salt (Tm ¼ 117.40 C). Particularly relevant is the
decrease of the initial melting points of the parent APIs (listed
in Table 1) by their conjugation with the cholinium cation. The
thermal properties (melting points and glass transition
temperatures) of the synthesized cholinium-based API-ILs and
parent APIs are summarized in Table 1.28128 | RSC Adv , 2014, 4, 28126 28132Fig. 2 shows the DSC trace for [N1112OH][PYR] (solid API-IL
with the highest Tm) at 5 and 10 C min
1 rates. [N1112OH][PYR]
remains liquid upon cooling (subcooled liquid state) until it
reaches a glass transition at low temperature. The glass transi-
tion with enthalpic relaxation is reached at 47.15 C in the
heating part of the cycle at a scan rate of 5 C min1 ( 45.99 C
at 10 C min1). Upon heating above the glass transition,
[N1112OH][PYR] exhibits an exothermic crystallization peak at
21.04 C (42.14 C at 10 C min1), cold crystallization
temperature, followed by an endothermic melting peak at
81.31 C (82.63 C at 10 C min1). This API-IL shows thermal
hysteresis.
Although the API-IL [N1112OH][PYR] is not liquid at room
temperature, or even at body temperature – a more relevant
temperature for pharmaceutical applications – (the Tm cut-oﬀ of
API-ILs for use within the body should be around 37 C), the two
DSC traces at scan rates of 5 and 10 C min1 (see Fig. 2)This journal is © The Royal Society of Chemistry 2014
Communication RSC Advancesindicate the potential of the cholinium-based API-ILs approach
to eﬀectively reduce the melting point of the parent API (pyr-
azinoic acid; lit.,44 Tm ¼ 225 C). Additionally, [N1112OH][PYR]
exhibits cold crystallization temperature and thus depending
on the cooling–heating cycles this API-IL can be easily handled
as liquid at room temperature, which is advantageous for the
development of new drug delivery systems, e.g. adsorption of
API-ILs onto mesoporous silica-based materials, that are
emerging as good candidates for controlled delivery of APIs.46
Thermal stability studies were performed by TGA analysis for
all the synthesized cholinium-based API-ILs. The onset points
of decomposition (Tonset) are listed in Table 1, and they point
out the inuence of the organic cation on the thermal stability
of these compounds. It can be observed that the thermal
stability of all API-ILs prepared in this work are very similar.
Solubility data were determined for the prepared cholinium-
based API-ILs ([N1112OH][NAL], [N1112OH][NIF], [N1112OH][PAS],
[N1112OH][PYR], and [N1112OH][PIC]), as well as for the parent
APIs (nalidixic acid, niumic acid, 4-amino-salicylic acid, pyr-
azinoic acid, and picolinic acid), in both water at 25 C and
buﬀer solutions suitable for dissolution tests at 37 C (body
temperature). In the latter case, simulated gastric uid without
enzymes – interchangeable with 0.1 N HCl (pH 1.0), simulated
intestinal uid without enzymes – interchangeable with phos-
phate standard buﬀer pH 6.8, and 0.15 M NaCl – isotonic ionic
strength were used. The solubility of the API-ILs and parent APIsTable 2 Solubility of cholinium-based API-ILs and parent APIs in water
at 25 C (0.1 C), where the solubility is the overall mean of three
independent experiments  standard deviation
API
Solubility (mg ml 1)
Cholinium based API ILs Parent APIsa
NAL 95.12  4.44 0.0282  0.0008
(lit.,47 0.031)
NIF 1124  37 0.0212  0.0008
(lit.,48–50 0.019, 0.040, 0.085)
PAS 101.3  2.8 4.554  0.221
(lit.,51–53 1.996,b 1.685,c 3.216d)
PYR 254.9  7.3 6.763  0.061
PIC 984.3  5.4 475.7  8.1
a Solubility data of the parent APIs reported in bibliography are also
depicted when available enclosed in parentheses. b @20 C. c @23 C.
d @30 C.
Fig. 3 Solubility of the prepared cholinium-based API-ILs and parent AP
This journal is © The Royal Society of Chemistry 2014in water at 25 C is summarized in Table 2 (solubility data of the
parent APIs reported in bibliography are also depicted when
available). As mentioned above, poor water solubility is a
limiting factor in the eﬃcacy and bioavailability of an API. Fig. 3
illustrates the water solubility at 25 C of the cholinium-based
API-ILs vs. parent APIs, and clearly demonstrates that the
cholinium-based API-ILs strategy is appropriate to overcome the
solubility problems of the parent APIs, and consequently
enhance their bioavailability and eﬃcacy. The most relevant
results were attained for [N1112OH][NAL] and [N1112OH][NIF],
whose parent APIs (nalidixic acid and niumic acid, respec-
tively) are classied as practically insoluble in water (solubility <
0.1 mg ml1), thus presenting dissolution-limited adsorption.26
Additionally, the determination of the solubility of an API
under physiological pH conditions is recommended. The pH–
solubility prole of the API should be determined at 37 C in
aqueous media with a pH in the range of 1–7.5. The solubility
results of the cholinium-based API-ILs and parents APIs in the
above-mentioned buﬀer solutions at 37 C are summarized in
Table 3. The comparative analysis (cholinium-based API-ILs vs.
parent APIs) of these solubilities, for the above-mentioned
practically insoluble in water nalidixic and niumic acids, is
depicted in Fig. 4. The solubilities in the buﬀer solutions at
37 C of the remaining cholinium-based API-ILs ([N1112OH][PAS],
[N1112OH][PYR], and [N1112OH][PIC]), and respective parent APIs
(4-amino-salicylic acid, pyrazinoic acid, and picolinic acid), are
shown in Fig. S2, S3, and S4 of the ESI.†
APIs display their specic potentials when they can penetrate
cells through the cell membranes. The study of Kawai et al.54
demonstrated that cholinium-like ILs clearly show the possi-
bility to penetrate cell membranes. For that, the proposed
cholinium-based API-ILs are considered to have a higher
potential to penetrate cell membranes than the parent APIs.
Ions cannot usually be transported through cell membranes by
a simple diﬀusion process. However, it is well known that
cholinium is transported through cell membranes for use as a
material for the biosynthesis of phosphatidylcholine and
acetylcholine.55,56 The prepared cholinium-based API-ILs may be
transported through cell membranes by a similar process.
Additionally, in our work on ampicillin-based ILs,7 the choli-
nium-based ampicillin IL showed higher water solubility and
octanol–water partition coeﬃcient than ampicillin. The choli-
nium-based ampicillin IL also showed higher octanol–waterIs in water at 25 C.
RSC Adv , 2014, 4, 28126 28132 | 28129
Table 3 Solubility of cholinium-based API-ILs and parent APIs in
buﬀer solutions suitable for dissolution testing, simulated gastric ﬂuid
(pH 1.0), simulated intestinal ﬂuid (pH 6.8) and isotonic ionic strength
aqueous solution (0.15 M NaCl), at 37 C (0.1 C). The solubility is the
overall mean of three independent experiments  standard deviation
Compound
Solubility (mg ml 1)
pH 1.0 pH 6.8 0.15 M NaCl
[N1112OH][NAL] 14.12  0.23 38.92  0.43 95.00  1.40
NAL 0.0515  0.0020 0.330  0.014 0.0570  0.0005
[N1112OH][NIF] 77.56  3.76 313.5  10.8 952.8  46.1
NIF 0.688  0.027 1.600  0.024 0.0861  0.0014
[N1112OH][PAS] 19.57  0.38 152.3  0.8 777.0  0.7
PAS 7.258  0.217 9.966  0.112 13.35  0.09
[N1112OH][PYR] 67.17  2.20 318.5  8.1 220.7  10.5
PYR 8.547  0.137 13.28  0.50 9.161  0.313
[N1112OH][PIC] 916.6  4.8 985.2  9.0 876.3  24.6
PIC 449.4  10.1 481.5  3.9 479.9  11.5
Fig. 4 Solubility of (a) [N1112OH][NAL] and nalidixic acid (parent API),
and (b) [N1112OH][NIF] and niﬂumic acid (parent API) in buﬀer solutions
suitable for dissolution testing, simulated gastric ﬂuid (pH 1.0), simu-
lated intestinal ﬂuid (pH 6.8) and isotonic ionic strength aqueous
solution (0.15 M NaCl), at 37 C.
RSC Advances Communicationpartition coeﬃcient than ampicillin sodium salt, though the
water solubility values are similar.
It is important to emphasize that the use of the cholinium
cation can eﬀectively modify the solubility in water and buﬀer
solutions suitable for dissolution testing of the parent APIs and
consequently enhances its bioavailability, eﬃcacy, and poten-
tial membrane permeability. Solving bioavailability problems of
active pharmaceutical ingredients is a major challenge for the
pharmaceutical industry, since nearly half of the new active
substances being identied in high-throughput screening are
either insoluble or poorly soluble in water.57
Before API-ILs can be used for pharmaceutical applications,
broad data such as cytotoxicity eﬀects is required to establish
biocompatibility. In this work, cytotoxicity assays were per-
formed using two diﬀerent human cell lines, Caco-2 colon
carcinoma cells and HepG2 hepatocellular carcinoma cells, that
are suitable and useful in vitro models for the intestinal barrier
and hepatic metabolism studies, respectively.58,59 Further,
cytotoxicity test in largely dediﬀerentiated cancer cells lines
such as Caco-2 and HepG2 cells provide a convenient screening
method for obtaining rst rough estimates for the toxic poten-
tial of chemical substances.60
In vitro cytotoxicity of representative cholinium-based API-
ILs ([N1112OH][NAL], [N1112OH][NIF] and [N1112OH][PYR]) and
parent APIs (nalidixic acid, niumic acid and pyrazinoic acid,
respectively) were measured using a proper MTS tetrazolium
assay.61 Due to the low solubility of the parent APIs in media-
based solutions, all the stock solutions of the API-ILs and parent
APIs were prepared rst in Milli-Q water (around parent API
solubility) and then the minimum possible dilution with
culture medium, composed of 0.5% FBS, was performed to
avoid precipitation (APIs and/or media nutrients). Cells were
exposed up to six independent dilutions of each API-IL and
parent API in 96-well plates for 24 h. Each plate contained a
negative control (cells with culture medium), and a positive
control (cells with 100% DMSO). Concentrations ranged from
500 to 6000 mM for [N1112OH][PYR] and pyrazinoic acid, from 20
to 58 mM for [N1112OH][NAL] and nalidixic acid, and from 10 to28130 | RSC Adv , 2014, 4, 28126 2813235 mM for [N1112OH][NIF] and niumic acid. Further details of
the MTS assay and method are provided in the ESI.†
The dose–response cytotoxicity curves are depicted in Fig. 5.
No signicant diﬀerence was observed in the metabolic activity
of the cells within the incubation of the cholinium-based API-
ILs and parent APIs with both cell lines in the concentration
range tested. The course of the cytotoxicity curves did not allow
a valid calculation of EC50 (i.e. eﬀective concentration reducing
cell viability to 50%) due to the limited solubility of the parent
APIs in the cell culture medium. Albeit, the studied concentra-
tions lie above/in range of the pharmacokinetic parameter
maximum plasma concentration of the parent APIs (170.03–
202.26 mM for pyrazinoic acid;62 53.82–61.58 mM for nalidixic
acid;63 20.20–25.16 mM for niumic acid64), which is above
possible intracellular concentrations.
The cell viability of the API-ILs is comparable to those of the
parent APIs (Fig. 5), indicating that the use of a modular IL
strategy based on the cholinium cation produced no signicant
eﬀect on the API system cytotoxicity. The analysis of the in vitro
cytotoxicity assays indicates the suitability and biocompatibility
of the proposed cholinium-based API-ILs for pharmaceutical
formulations.Conclusions
In the present work, we report ve new cholinium-based ILs
with active pharmaceutical anions directly derived from the
“APIs pool” (nalidixic acid, niumic acid, 4-amino-salicylic acid,This journal is © The Royal Society of Chemistry 2014
Fig. 5 Cytotoxicity proﬁle of (a) [N1112OH][NAL] and nalidixic acid, (b)
[N1112OH][NIF] and niﬂumic acid, and (c) [N1112OH][PYR] and pyrazinoic
acid in the Caco-2 and HepG2 cell lines. Both Caco-2 and HepG2 cells
were exposed for 24 h to the respective cholinium-based API-IL and
parent API at the concentrations shown and assessed for metabolic
activity as described in the ESI.†
Communication RSC Advancespyrazinoic acid, and picolinic acid). The cholinium cation, due
to its particular properties, biocompatibility, low toxicity, high
water solubility and numerous functions supported in organ-
isms, improves the aqueous solubility and the potential to
penetrate cell membranes of the parent APIs. A modular IL
strategy based on the benign, cheap and available cholinium
cation can provide a platform for improved activity and new
treatment options of pharmaceuticals. The feasibility to surpass
problems such as reduced aqueous solubility and bioavail-
ability, and polymorphism, might give discarded APIs a second
life, or stimulate the acceptance of new APIs candidates. Cyto-
toxicity test on human cells lines have furthermore substanti-
ated that cholinium-based API-ILs and parent APIs display
similar cytotoxic response which spur opportunities for creating
further advances in pharmaceutical challenges. The pharma-
cological action of the prepared API-ILs should be tested to
verify if a potential synergetic eﬀect between the ion pair exists,This journal is © The Royal Society of Chemistry 2014consequently leading to new therapeutic advantages. The
development of API-ILs represents a paradigm that oﬀers many
opportunities related to drug development and delivery. This is
a very appealing and fast moving eld of research that may play
a signicant role in the future of healthcare, taking ILs from the
benchtop to the bedside.
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